

11 October 2022

Market Announcements Office  
ASX Limited  
20 Bridge Street  
Sydney NSW 2000

Dear Sir / Madam

**Bod Australia Limited (ASX: BOD)**  
**Notice under section 708A(5) of the Corporations Act 2001 (Cth)**

This notice is given by Bod Australia Limited (ASX:BOD) ACN 601 225 441 (the **Company** or **BOD**) under section 708(5)(e) of the *Corporations Act 2001* (Cth) (**Act**).

BOD refers to the pro rata, non-accelerated, non-renounceable entitlement offer (**Entitlement Offer**) of four fully paid BOD ordinary shares (**Shares**) for every 17 Shares announced on 1 September 2022.

In accordance with the announcement of the results of the Entitlement Offer on 4 October 2022, the Company on 11 October 2022 issued 16,849,603 Shares to sophisticated and professional investors pursuant to the Shortfall Offer.

For the purposes of section 708A(6) of the Act, BOD advises that:

1. The Shares to be issued pursuant to the Shortfall Offer were offered for issue without disclosure under Part 6D.2 of the Act.
2. This notice is being given under section 708A(5)(e) of the Act.
3. As at the date of this notice BOD has complied with:
  - a. the provisions of Chapter 2M of the Corporations Act as they apply to BOD; and
  - b. sections 674 and 674A of the Act.
4. As at the date of this notice, there is no excluded information of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act.

**Authorised for release by the Company Secretary of BOD.**

ENDS

**Further Information**

**Investors:**

Stephen Kelly  
Company Secretary  
Info@bodaustralia.com  
+61 415 719 695

**Media:**

Henry Jordan  
Six Degrees Investor Relations  
Henry.jordan@sdir.com.au  
+61 431 271 538

**CONTACT**

Level 1, 377 New South Road, Double Bay NSW 2028 T +61 2 9199 5018 E info@bodscience.com W bodscience.com

### **About Bod Australia**

Bod Australia Limited (ASX:BOD) Bod is a cannabis focused drug development and product innovation company.

Bod is focused on progressing R&D and a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for the consumer and medical markets.

The company has a number of existing partnerships with large corporate groups and collaborations with leading research partners to advance the use of CBD.

For more information on BOD please visit <http://bodaustralia.com/>

### **IMPORTANT INFORMATION**

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, registration under the US Securities Act and applicable US state securities laws.

### **CONTACT**

Level 1, 377 New South Road, Double Bay NSW 2028 **T** +61 2 9199 5018 **E** [info@bodscience.com](mailto:info@bodscience.com) **W** [bodscience.com](http://bodscience.com)